Phaseline

Companies › Verity Pharmaceuticals

Verity Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Feb 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Verity-BCG
Live attenuated Mycobacterium bovis BCG (Russian strain) - immunotherapeutic agent for int
–Phase 3Bladder CancerFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05037279Verity-BCGPhase 3Bladder CancerOncologyFeb 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

SecuraBio Fidia Farmaceutici Sumitomo Pharma Switzerland Eleison Pharmaceuticals Tianjin Hemay Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.